Breakthru Medicine

Coming – December 17

A Groundbreaking Approach To An $18B Cancer Market

Date and Time

December 17

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Breakthru Medicine is developing precision cancer therapies targeting currently undruggable tumors. It is an $18B+ solid cancer market with massive unmet need. The preclinical data demonstrates an industry leading efficacy across multiple major cancer indications with this novel mechanism of action.

The company is also developing two platform technologies with two high-value modalities—antibody drug conjugates with differentiated, novel payloads and molecular glues to drug targets deemed untreatable by conventional methods. These novel approaches have the potential to extend hundreds of thousands of lives across pancreatic, breast, prostate, colorectal and lung cancers.

The company is in stealth mode with very little information available online, so if you’re interested in learning more about Breakthru Medicine, please register for this webinar to reserve your spot.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.